Takagi Hisato, Hari Yosuke, Nakashima Kouki, Yokoyama Yujiro, Ueyama Hiroki, Kuno Toshiki, Ando Tomo
Department of Cardiovascular Surgery, Shizuoka Medical Center, Shizuoka, Japan.
Department of Cardiovascular Surgery, Kitasato University School of Medicine, Sagamihara, Japan.
J Card Surg. 2020 Mar;35(3):536-543. doi: 10.1111/jocs.14409. Epub 2019 Dec 30.
To determine whether preprocedural left ventricular (LV) diastolic dysfunction impairs midterm mortality after transcatheter aortic valve implantation (TAVI) for patients with severe aortic stenosis (AS), we performed a meta-analysis of currently available evidence.
We identified all studies investigating impact of preprocedural severity of LV diastolic dysfunction on midterm (≥1-year) all-cause mortality after TAVI for patients with AS through a search of databases (MEDLINE and EMBASE) until September 2019. From each study, we extracted an adjusted (if unavailable, unadjusted) hazard ratio (HR) of midterm mortality. We pooled study-specific estimates in the random-effects model.
Ten eligible studies with a total of 2380 patients with AS undergoing TAVI were identified. In accordance with pooled analyses, higher-grade preprocedural LV diastolic dysfunction was associated with significantly worse midterm all-cause mortality after TAVI compared to lower-grade dysfunction (HR for grade II vs I, 1.15; P = .002; HR for grade III vs I, 1.35; P = .001; HR for grade III vs II; 1.16, P = .002; HR for grade II-III vs I, II-III vs 0-I, or III vs I-II, 1.34; P < .00001 [primary meta-analysis]; HR per grade, 1.16; P = .003). No funnel plot asymmetry for the primary meta-analysis (for grade II-III vs I, II-III vs 0-I, or III vs I-II) was identified, which probably indicated no publication bias (P = .381 by the linear-regression test).
Higher-grade preprocedural LV diastolic dysfunction was associated with worse midterm all-cause mortality after TAVI for patients with AS compared to lower-grade dysfunction.
为了确定在经导管主动脉瓣植入术(TAVI)治疗严重主动脉瓣狭窄(AS)患者时,术前左心室(LV)舒张功能障碍是否会影响中期死亡率,我们对现有证据进行了荟萃分析。
我们通过检索数据库(MEDLINE和EMBASE)直至2019年9月,找出了所有研究术前LV舒张功能障碍严重程度对TAVI治疗AS患者中期(≥1年)全因死亡率影响的研究。从每项研究中,我们提取了中期死亡率的调整后(若不可得,则为未调整)风险比(HR)。我们在随机效应模型中汇总了各研究的估计值。
共确定了10项符合条件的研究,总计2380例接受TAVI治疗的AS患者。根据汇总分析,与较低级别功能障碍相比,较高级别术前LV舒张功能障碍与TAVI术后中期全因死亡率显著更差相关(II级与I级相比的HR为1.15;P = 0.002;III级与I级相比的HR为1.35;P = 0.001;III级与II级相比的HR为1.16;P = 0.002;II - III级与I级、II - III级与0 - I级或III级与I - II级相比的HR为1.34;P < 0.00001[主要荟萃分析];每级HR为1.16;P = 0.003)。未发现主要荟萃分析(II - III级与I级、II - III级与0 - I级或III级与I - II级相比)的漏斗图不对称性,这可能表明不存在发表偏倚(线性回归检验P = 0.381)。
与较低级别功能障碍相比,较高级别术前LV舒张功能障碍与TAVI治疗AS患者的中期全因死亡率更差相关。